The specialty pharmaceutical firm Antares Pharma Inc (NASDAQ:ATRS) has seen its stock trade within a range in recent days. That being said, it should be noted that a stock which trades within a range can often breakout as well and hence, it might be a good move to keep an eye on the Antares stock.
As it happens, last week, the company announced that Idorsia Ltd, its partner, started the registration study for the evaluation of safety as well as efficacy of its product P2Y. It is a subcutaneous selatogrel that can be administered by patients themselves and meant to help with the treatment of acute myocardial infarction.
In this regard, it is also necessary to keep in mind that the product is supposed to be used in conjunction with Quickshot auto-injector that has been created by Antares Pharma. The Chief Executive Officer and President of the company Robert F.
Apple spoke about the development as well. He stated that the close collaboration between the two companies has been one of the main factors behind the achievement of the important milestone of the beginning of the Phase 3 study by Idorsia. It remains to be seen if the stock comes into focus among investors today.
On Friday, ATRS stock jumped 2.28% at $4.48 with more than 880k shares, compared to its average volume of 839k shares. The stock had moved within a range of $4.3600 – 4.5000 after opening the trade at $4.41. Over the past 52-week, the stock has been trading within a range of $2.5300 – 5.0700.